🇺🇸 FDA
Pipeline program

CEP-26401

C26401/1111

Phase 1 small_molecule completed

Quick answer

CEP-26401 for Cognitive Impairment is a Phase 1 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Indication
Cognitive Impairment
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials